This approach may not be reliable for gastric tumors, which display heterogeneous HER2 expression, and may contribute to the observed poor clinical response to pertuzumab/trastuzumab combinations in patients with gastric cancers (19). The gene discussed is ERBB2; the disease is gastric neoplasm.